

Ola Weiland

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5714651/ola-weiland-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

5,546
citations

30
h-index

73
g-index

101
ext. papers

6,096
ext. citations

9.3
avg, IF

4.95
L-index

#	Paper	IF	Citations
100	Value appropriation in hepatitis C. <i>European Journal of Health Economics</i> , 2021 , 1	3.6	1
99	Absence of interferon- λ enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 855-861	2.4	
98	REPLY. <i>Hepatology</i> , 2021 , 74, 1127-1128	11.2	
97	Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 142-146	3.4	2
96	High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 574-580	2.4	0
95	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , 2020 , 72, 1177-1190	11.2	21
94	Significant decrease in injection risk behaviours among participants in a needle exchange programme. <i>Infectious Diseases</i> , 2020 , 52, 336-346	3.1	10
93	Hepatitis C elimination - Macro-elimination. <i>Liver International</i> , 2020 , 40 Suppl 1, 61-66	7.9	2
92	Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	5
91	Management of hepatitis B virus infection, updated Swedish guidelines. <i>Infectious Diseases</i> , 2020 , 52, 1-22	3.1	11
90	Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 319-327	2.4	3
89	Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. <i>Journal of Hepatology</i> , 2019 , 70, 1019-1023	13.4	36
88	Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 337-349	3.4	24
87	Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. <i>Infectious Diseases</i> , 2019 , 51, 131-139	3.1	9
86	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. <i>Infectious Diseases</i> , 2018 , 50, 569-583	3.1	13
85	Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 971-978	2.8	18
84	Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 802-810	3.4	11

83	Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1452-1461	3.4	17
82	<i>Staphylococcus aureus</i> bacteraemia and endocarditis - epidemiology and outcome: a review. <i>Infectious Diseases</i> , 2018 , 50, 175-192	3.1	50
81	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. <i>BMC Infectious Diseases</i> , 2017 , 17, 45	4	16
80	Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. <i>Infectious Diseases</i> , 2017 , 49, 728-736	3.1	22
79	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 1022-1028	2.4	25
78	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. <i>Infectious Diseases</i> , 2017 , 49, 561-575	3.1	11
77	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017 , 66, 485-493	13.4	160
76	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 61-68	2.4	11
75	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. <i>PLoS ONE</i> , 2017 , 12, e0179764	3.7	21
74	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2016 , 63, 723-9	11.6	28
73	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. <i>Infectious Diseases</i> , 2016 , 48, 251-261	3.1	11
72	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016 , 22, 446-58	4.5	66
71	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , 2016 , 65, 1861-1870	19.2	146
70	Incidence and outcome of <i>Staphylococcus aureus</i> endocarditis--a 10-year single-centre northern European experience. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 772-8	9.5	10
69	Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. <i>Infectious Diseases</i> , 2015 , 47, 209-17	3.1	3
68	Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , 2015 , 15, 27-35	25.5	52
67	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015 , 64, 948-56	19.2	90
66	Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients. <i>PLoS ONE</i> , 2015 , 10, e0118643	3.7	11

65	ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. <i>Gastroenterology</i> , 2014 , 147, 359-365.e1	13.3	294
64	Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. <i>Journal of Hepatology</i> , 2014 , 61, 957-61	13.4	29
63	Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. <i>New England Journal of Medicine</i> , 2014 , 370, 1594-603	59.2	690
62	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014 , 60, 913-9	13.4	33
61	Sofosbuvir and ribavirin in HCV genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014 , 370, 1993-2001	59.2	671
60	The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir. <i>PLoS ONE</i> , 2014 , 9, e105665	3.7	7
59	1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S41-S42	1	
58	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. <i>Journal of Hepatology</i> , 2014 , 61, 228-34	13.4	80
57	A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2013 , 57, 230-6	11.6	182
56	Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. <i>Molecular Therapy</i> , 2013 , 21, 1796-805	11.7	55
55	Impact of IL28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. <i>PLoS ONE</i> , 2013 , 8, e80172	3.7	22
54	Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up. <i>ISRN Transplantation</i> , 2013 , 2013, 1-8		0
53	Telaprevir for retreatment of HCV infection. <i>New England Journal of Medicine</i> , 2011 , 364, 2417-28	59.2	1279
52	Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 641-5	3.4	20
51	Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 867-77	2.4	10
50	Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. <i>Journal of General Virology</i> , 2001 , 82, 1299-1308	4.9	30
49	Humoral and cellular immune responses to the GB virus C/hepatitis G virus envelope 2 protein. <i>Journal of Medical Virology</i> , 2000 , 62, 334-344	19.7	2
48	Interferon and ribavirin combination therapy: indications and schedules. <i>Forum: Trends in Experimental and Clinical Medicine</i> , 2000 , 10, 22-8		2

47	Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 1999 , 31, 115-8		13
46	Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. <i>Hepatology</i> , 1998 , 28, 219-24	11.2	17
45	GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors. <i>Journal of Medical Virology</i> , 1998 , 54, 75-9	19.7	11
44	Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. <i>Journal of Medical Virology</i> , 1998 , 56, 33-8	19.7	28
43	Activated Cellular Immunity in Chronic Hepatitis C. <i>Hematology</i> , 1996 , 1, 75-8	2.2	
42	Utility of an anonymous questionnaire for the identification of a primary transmission route and possible secondary transmission in adults with acute hepatitis B virus infection. <i>European Journal of Epidemiology</i> , 1996 , 12, 319-22	12.1	2
41	Efficacy of Human Leucocyte Alpha-Interferon Treatment for Chronic Hepatitis C Virus Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 319-324		12
40	Hepatitis E virus infections in patients with acute hepatitis non-A-D in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 1995 , 27, 543-6		20
39	Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. <i>Hepatology</i> , 1995 , 21, 918-922	11.2	77
38	Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. <i>Liver</i> , 1994 , 14, 169-74		11
37	Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. <i>Scandinavian Journal of Infectious Diseases</i> , 1994 , 26, 468-70		32
36	Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications. <i>Journal of Medical Virology</i> , 1994 , 44, 272-9	19.7	102
35	Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. <i>Scandinavian Journal of Infectious Diseases</i> , 1994 , 26, 383-9		6
34	Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1994 , 26, 263-70		29
33	Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. <i>Liver</i> , 1993 , 13, 274-8		82
32	Prevalence of Hepatitis B Virus Markers among Intravenous Drug Abusers in Stockholm: Impact of Heterosexual Transmission. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 8-13		9
31	Interferon Alpha-2b Treatment in an HIV-infected Patient with Hepatitis B Virus Induced Nephrotic Syndrome. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 133-135		7
30	Serum HCV RNA Levels in Patients with Chronic Hepatitis C Given a Second Course of Interferon alpha-2b Treatment after Relapse following Initial Treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 25-30		23

29	Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. <i>Journal of Medical Virology</i> , 1993 , 39, 57-61	19.7	55
28	Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. <i>Journal of Medical Virology</i> , 1993 , 41, 99-102	19.7	78
27	Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 1993 , 25, 25-30		7
26	Peripheral blood lymphocyte subsets in patients with chronic hepatitis C--effects of interferon treatment. <i>Liver</i> , 1992 , 12, 161-7		13
25	Seroconversion to hepatitis C virus antibodies in patients with acute posttransfusion non-A, non-B hepatitis in Sweden with a second generation test. <i>Scandinavian Journal of Infectious Diseases</i> , 1992 , 24, 15-20		20
24	Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. <i>Scandinavian Journal of Infectious Diseases</i> , 1992 , 24, 423-9		41
23	Hepatitis C: virology, epidemiology, clinical course, and treatment. <i>Scandinavian Journal of Gastroenterology</i> , 1992 , 27, 337-42	2.4	18
22	Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. <i>Liver</i> , 1991 , 11, 30-8		38
21	Incidence of hepatitis and seroconversion to hepatitis C virus after open-heart surgery in transfused and non-transfused patients in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 1991 , 23, 25-9		11
20	Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders. <i>Scandinavian Journal of Infectious Diseases</i> , 1991 , 23, 413-20		17
19	Sandfly fever among Swedish tourists. <i>Scandinavian Journal of Infectious Diseases</i> , 1991 , 23, 451-7		61
18	Positive reactivity with anti-HCV ELISA in patients with autoimmune hepatitis--not confirmed with a neutralization test. <i>Scandinavian Journal of Infectious Diseases</i> , 1991 , 23, 127-8		7
17	Application of a numerical scoring system for assessment of histological outcome in patients with chronic posttransfusion non-A, non-B hepatitis with or without antibodies to hepatitis C. <i>Liver</i> , 1990 , 10, 257-63		22
16	Serum levels of the aminoterminal propeptide of type III procollagen and hyaluronan during resolving and nonresolving posttransfusion non-A, non-B hepatitis. <i>Scandinavian Journal of Infectious Diseases</i> , 1990 , 22, 11-7		5
15	Prevalence of hepatitis B virus markers in Icelandic outpatients and hospital personnel in 1979 and in 1987. <i>Scandinavian Journal of Infectious Diseases</i> , 1990 , 22, 149-53		1
14	False positive reactivity for antibodies against hepatitis C virus in patients with autoimmune chronic active hepatitis?. <i>Scandinavian Journal of Infectious Diseases</i> , 1990 , 22, 377-8		8
13	Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. <i>Journal of Hepatology</i> , 1990 , 11 Suppl 1, S57-62	13.4	55
12	Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison. <i>Liver</i> , 1989 , 9, 120-7		41

11	A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. <i>Scandinavian Journal of Infectious Diseases</i> , 1989 , 21, 617-25		66
10	Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. <i>Liver</i> , 1988 , 8, 184-8		50
9	The application of a numerical scoring system for evaluating the histological outcome in patients with chronic hepatitis B followed in long-term. <i>Hepatology</i> , 1988 , 8, 98-103	11.2	15
8	Non-A, non-B hepatitis after open-heart surgery in Stockholm: declining incidence after introduction of restrictions for blood donations due to the human immunodeficiency virus. <i>Scandinavian Journal of Infectious Diseases</i> , 1988 , 20, 371-6		24
7	Alpha interferon treatment of chronic non-A, non-B hepatitis caused by intravenous gammaglobulin. <i>Scandinavian Journal of Infectious Diseases</i> , 1988 , 20, 231-2		7
6	Hepatitis A. Aspects on prophylaxis and a comparison with hepatitis B and hepatitis non-A, non-B on epidemiology and prognosis. <i>Scandinavian Journal of Infectious Diseases</i> , 1981 , 28, 1-73		3
5	Acute viral hepatitis, types A, B and non-A, non-B: a prospective study of the epidemiological, laboratory and prognostic aspects in 280 consecutive cases. <i>Scandinavian Journal of Infectious Diseases</i> , 1981 , 13, 247-55		32
4	Prevalence of antibody against hepatitis A in Sweden in relation to age and type of community. <i>Scandinavian Journal of Infectious Diseases</i> , 1980 , 12, 171-4		31
3	Prevalence of Hepatitis B Virus Markers among Intravenous Drug Abusers in Stockholm: Impact of Heterosexual Transmission		3
2	Serum HCV RNA Levels in Patients with Chronic Hepatitis C Given a Second Course of Interferon alpha-2b Treatment after Relapse following Initial Treatment		11
1	Interferon Alpha-2b Treatment in an HIV-infected Patient with Hepatitis B Virus Induced Nephrotic Syndrome		2